News

The biopharmaceutical company is testing with multiple U.S. military branches at Northern Strike to provide Bexson’s BB106 ketamine therapy for pain management for contested environments.

In September, the company won patent protection for its SeValent novel formulation technology that would enable at-home therapy with a wearable device instead of in-hospital IV delivery. The on-body delivery system, developed jointly with Stevanato Group, includes a prefilled sterilized subcutaneous pump. While Bexson is first exploring ketamine, the system could be used with numerous drug types, including antibiotics, psychedelics and new chemical entities with poor oral bioavailability.

In this article, Paolo Golfetto, Drug Delivery Systems Business Development Director at Stevanato Group, and Sheldon Moberg, Senior Vice-President of Drug Delivery at Bexson Biomedical, discuss an urgent requirement to meet an unmet patient need.

Bexson Biomedical recently signed a deal with the Stevanato Group to develop a subcutaneous delivery system of ketamine.

Medications that manage post-operative pain are some of the main entry points to opioid addiction and overdose in the US, which kills roughly 50,000 Americans each year. Alternatives for pain management are thus crucial to address this issue.

Over the last several years, opioid addiction has become a major issue. Despite efforts to combat this drug epidemic, 2019 saw over 50,000 deaths because of this issue. Likewise, over 40 percent of these deaths were related to pharmaceuticals like oxycontin.

Currently in the middle of a $4 million Series A funding round, Bexson is still in pre-clinical development. The research stage company will start animal testing this year, with plans to launch a phase one clinical trial in 2021. Peterson says if all goes well, Bexson’s wearable ketamine delivery system could be approved by the FDA for post-op pain by 2026.